Format

Send to

Choose Destination
See comment in PubMed Commons below
Trends Cardiovasc Med. 2013 Oct;23(7):242-9. doi: 10.1016/j.tcm.2013.01.002. Epub 2013 Mar 15.

GPCR biased ligands as novel heart failure therapeutics.

Author information

1
Trevena Inc, 1018 West 8th Ave, Suite A, King of Prussia, PA 19406. Electronic address: jviolin@trevenainc.com.

Abstract

G protein-coupled receptors have been successfully targeted by numerous therapeutics including drugs that have transformed the management of cardiovascular disease. However, many GPCRs, when activated or blocked by drugs, elicit both beneficial and adverse pharmacology. Recent work has demonstrated that in some cases, the salutary and deleterious signals linked to a specific GPCR can be selectively targeted by "biased ligands" that entrain subsets of a receptor's normal pharmacology. This review briefly summarizes the advances and current state of the biased ligand field, focusing on an example: biased ligands targeting the angiotensin II type 1 receptor. These compounds exhibit unique pharmacology, distinct from classic agonists or antagonists, and one such molecule is now in clinical development for the treatment of acute heart failure.

PMID:
23499300
DOI:
10.1016/j.tcm.2013.01.002
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center